Merck to spin-off biosimilar drugs business to focus on Keytruda

Merck will retain its cancer drugs, including blockbuster cancer therapy Keytruda, vaccines, hospital and animal health businesses, the company said.

US: U.S. drugmaker Merck & Co Inc said on Wednesday it was planning to spin off its women's health, biosimilar drugs and legacy products into a new publicly-traded company.

Also Read: Merck Keytruda, Chemotherapy Combination Shows Mixed Results In Phase 3 Trial For Lung Cancer

Merck will retain its cancer drugs, including blockbuster cancer therapy Keytruda, vaccines, hospital and animal health businesses, the company said.

The company also reported a 29% higher fourth-quarter profit of $2.36 billion, helped by higher sales for Keytruda.

Also Read: Merck's Antibacterial Med Dificid Gets FDA Nod In Pediatric Indication